Case Report
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 102690
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.102690
Precision treatment for human epidermal growth factor receptor 2-amplified advanced rectal cancer: A case report
Xia Xiao, Qing-Wen Wang, Zheng-Yang Zhou, Lei-Sheng Wang, Pei Huang
Xia Xiao, Pei Huang, Department of Oncology, Wuxi No. 2 People’s Hospital, Jiangnan University Medical Center, Wuxi 214002, Jiangsu Province, China
Qing-Wen Wang, Zheng-Yang Zhou, Lei-Sheng Wang, Wuxi Medical College, Jiangnan University, Wuxi 214122, Jiangsu Province, China
Co-first authors: Xia Xiao and Qing-Wen Wang.
Co-corresponding authors: Lei-Sheng Wang and Pei Huang.
Author contributions: Xiao X and Wang QW collected the patient data and drafted the manuscript, they contributed equally to this article, they are the co-first authors of this manuscript; Zhou ZY, Wang LS, and Huang P revised the manuscript; Wang LS and Huang P contributed equally to this article, they are the co-corresponding authors of this manuscript; and all the authors read and approved the final manuscript.
Supported by the Jiangsu Provincial Health and Family Planning Commission Personnel Talent Project, No. R2017005.
Informed consent statement: Written informed consent was obtained from the patient to publish this report and any accompanying images. This case has been approved by the patient.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lei-Sheng Wang, Wuxi Medical College, Jiangnan University, Binhu Road, Wuxi 214122, Jiangsu Province, China. 6222809140@stu.jiangnan.edu.cn
Received: October 28, 2024
Revised: January 23, 2025
Accepted: February 17, 2025
Published online: April 15, 2025
Processing time: 151 Days and 4.7 Hours
Core Tip

Core Tip: Human epidermal growth factor receptor 2-amplified advanced rectal cancer was unresponsive to conventional chemotherapy and targeted therapy in a Chinese patient. This study demonstrated the synergistic effect of combining an immune checkpoint inhibitor with pyrotinib, providing a new treatment strategy for patients with advanced rectal cancer. Following treatment with an immune checkpoint inhibitor in combination with pyrotinib, the patient achieved significant therapeutic effects as evidenced by a marked reduction in tumour size.